Press release
Inflammation and Pain Post-Cataract Surgery Market is projected to reach USD 3.91 billion by 2034
Inflammation and Pain Post-Cataract Surgery
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70915
Cataract surgery is one of the most commonly performed surgical procedures globally, and postoperative inflammation and pain management is essential to ensure visual recovery, minimize complications such as cystoid macular edema (CME), and improve patient satisfaction. Corticosteroids, NSAIDs, multimodal fixed-dose combinations, and sustained-release intraocular drug delivery technologies form the core of the treatment landscape.
Key Market Highlights
• 2024 Market Size: USD 2.34 billion
• 2034 Forecast: USD 3.91 billion
• CAGR (2025-2034): 5.3%
• Largest Segment: Topical corticosteroids
• Fastest-Growing Segment: Sustained-release intraocular drug delivery systems
Epidemiology & Clinical Insights
1. Rising Global Cataract Burden
• Cataracts account for ~45% of global blindness.
• Over 28 million cataract surgeries were performed globally in 2024.
• Aging populations in Asia, Europe, and North America significantly expand demand.
2. Postoperative Inflammation
Inflammation after phacoemulsification or laser-assisted cataract surgery is caused by:
• Surgical trauma
• Release of prostaglandins
• Immune response activation
3. Symptoms
• Ocular pain
• Redness
• Light sensitivity
• Swelling
• Reduced visual acuity
4. Risk Factors
Higher inflammation risk occurs in:
• Diabetes patients
• Uveitis history
• Intraoperative complications
• Multifocal/premium IOL implantation
Market Growth Drivers
1. Strong Increase in Global Cataract Surgical Volumes
Demographic shifts and improved access to ophthalmic care expand market size.
2. Preference for Fixed-Dose Combination (FDC) Therapies
Convenience improves adherence, especially among elderly patients.
3. Emergence of Sustained-Release Drug Delivery
Products such as intracanalicular inserts and intraocular steroid implants reduce drop burden.
4. Growth of Premium IOL Adoption
Premium IOL recipients expect faster and clearer vision recovery, increasing demand for high-performance postoperative medications.
5. Improved Surgical Techniques
Femtosecond-laser and micro-incision cataract surgery reduce inflammation but require precise anti-inflammatory management.
Market Restraints
• High cost of sustained-release technologies
• Patient non-compliance with topical drops
• Risk of steroid-induced IOP elevation
• Variable insurance reimbursement across regions
Market Opportunities
1. Sustained-Release & Injectable Therapies
Significant potential for minimal-drop or drop-free postoperative treatment models.
2. Novel NSAID & Steroid Molecules
Improved penetration, lower toxicity, and extended duration.
3. Digital Compliance Platforms
Smart ophthalmic drug delivery devices and reminders.
4. Expansion into Emerging Markets
Large cataract burden in India, China, Brazil, and Africa.
5. Combination Anti-Inflammatory & Anti-Infective Therapies
Increasing adoption of simplified postoperative regimens.
Segmentation Overview
By Drug Class
• Corticosteroids (prednisolone acetate, dexamethasone, loteprednol)
• Nonsteroidal anti-inflammatory drugs (NSAIDs) (bromfenac, nepafenac)
• Fixed-dose combinations (FDCs)
• Analgesics
• Sustained-release implants/inserts
By Route of Administration
• Topical eye drops
• Intracanalicular inserts
• Intraocular injections / implants
By End User
• Hospitals
• Ophthalmic clinics
• Ambulatory surgical centers
• Retail & online pharmacies
Explore Full Report here: https://exactitudeconsultancy.com/reports/70915/inflammation-and-pain-post-cataract-surgery-market
Regional Insights
North America - Largest Market
High adoption of sustained-release inserts, strong ophthalmology infrastructure, and favorable reimbursement.
Europe - Strong Uptake of Advanced Drug Delivery
Germany, France, UK, Spain, and Italy drive strong usage of combination drops and NSAIDs.
Asia Pacific - Fastest Growing
Largest cataract burden globally; increasing IOL adoption and government-supported eye health programs.
Latin America - Developing
Growth led by Brazil, Mexico, Colombia, and Chile.
Middle East & Africa - Emerging
Increasing cataract surgery accessibility and public eye-health initiatives.
Competitive Landscape
Major companies active in the postoperative cataract inflammation and pain market include:
• Allergan (AbbVie)
• Alcon
• Bausch + Lomb
• Sun Pharma
• Santen Pharmaceutical
• Novartis
• Ocular Therapeutix
• EyePoint Pharmaceuticals
• Harrow Health
• Hikma Pharmaceuticals
Key areas of R&D include sustained-release steroid implants, novel NSAID formulations, and combination therapy optimization.
Recent Market Developments
• Increased use of intracanalicular dexamethasone inserts (drop-free therapy)
• New fixed-dose combination steroid-NSAID drops entering global markets
• AI and digital adherence tools in ophthalmology gaining adoption
• Premium IOL growth boosting demand for high-efficacy anti-inflammatory regimens
• Next-generation topical molecules offering longer retention and reduced dosing frequency
Future Outlook (2025-2034)
The market will expand steadily as:
• Drop-free and sustained-release therapy models gain global traction
• Premium cataract surgery adoption continues rising
• Emerging markets scale their surgical capacity
• Innovation in ophthalmic drug delivery increases treatment convenience and safety
By 2034, the global market is expected to reach USD 3.91 billion, driven by expanding cataract surgery volumes and advanced postoperative care technologies.
This report is also available in the following languages : Japanese (白内障手術後の炎症と痛み), Korean (백내장 수술 후 염증 및 통증), Chinese (白内障手术后的炎症和疼痛), French (Inflammation et douleur après une opération de la cataracte), German (Entzündung und Schmerzen nach Kataraktoperation), and Italian (Infiammazione e dolore dopo l'intervento di cataratta), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/request-sample/70915
Our More Reports:
Chronic Gout Market
https://exactitudeconsultancy.com/reports/70993/chronic-gout-market
Ankylosing spondylitis Patient Pool Market
https://exactitudeconsultancy.com/reports/71014/ankylosing-spondylitis-patient-pool-market
Ocular Inflammation and Pain Market
https://exactitudeconsultancy.com/reports/72265/ocular-inflammation-and-pain-market
Refractory Gout Market
https://exactitudeconsultancy.com/reports/72657/refractory-gout-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Inflammation and Pain Post-Cataract Surgery Market is projected to reach USD 3.91 billion by 2034 here
News-ID: 4311461 • Views: …
More Releases from Exactitude Consultancy
Non-Postoperative Acute Pain Market is projected to reach USD 29.76 billion by 2 …
The global Non-Postoperative Acute Pain Market was valued at USD 19.84 billion in 2024 and is projected to reach USD 29.76 billion by 2034, growing at a CAGR of 4.1% during 2025-2034. Growth is driven by rising incidence of trauma, musculoskeletal injuries, dental procedures, acute infections, and chronic disease flare-ups that require short-term pain control. Increasing emergency room visits, expanding geriatric populations, and innovations in non-opioid analgesics are also shaping…
Chronic Venous Insufficiency (CVI) Market Growing at a CAGR of around 5.4%
Chronic Venous Insufficiency (CVI) Market
The Chronic Venous Insufficiency (CVI) Market was valued at ~USD 3.6 billion in 2024 and is projected to reach ~USD 6.1 billion by 2034, growing at a CAGR of around 5.4%. Increasing prevalence of varicose veins, rising geriatric population, and strong adoption of minimally invasive venous procedures are key drivers of market expansion.
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/71275
Key Market Drivers
• Growing number of…
GM2 Gangliosidosis Market is projected to reach USD 332 million by 2034
The global GM2 Gangliosidosis Market-covering Tay-Sachs disease, Sandhoff disease, and related GM2 deficiency disorders-was valued at USD 152 million in 2024 and is projected to reach USD 332 million by 2034, growing at a CAGR of 8.1% during 2025-2034. Market growth is driven by increasing research in gene therapy, better awareness of lysosomal storage disorders (LSDs), advancements in newborn screening, and growth of specialized centers for rare diseases.
Download Full PDF…
Diamond-Blackfan Anemia (DBA) Market Growing at a CAGR of around 7.1%
Diamond-Blackfan Anemia (DBA) Market
The Diamond-Blackfan Anemia (DBA) Market was valued at ~USD 210 million in 2024 and is projected to reach ~USD 420 million by 2034, growing at a CAGR of around 7.1%. Growth is driven by expanding diagnosis of inherited bone marrow failure syndromes, increasing use of corticosteroid therapy, and rising interest in gene-based treatments.
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/71277
Key Market Drivers
• Better identification of ribosomal…
More Releases for Inflammation
United States Chronic Inflammation Treatment Market 2025 | Granulomatous inflamm …
Leander, Texas and Tokyo, Japan - Nov.24.2025
As per DataM intelligence research report" The global chronic inflammation treatment market is expected to reach at a Significant CAGR during the forecast period 2024-2031." Advances in biologics and rising autoimmune conditions are shaping the chronic inflammation treatment landscape.
Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/chronic-inflammation-treatment-market?Prasad
United States: Recent Industry Developments
✅ In November 2025, Pfizer launched a next-generation chronic inflammation therapy…
Inflammation Test Kit Market Trends, Demand, and Future Outlook
The global inflammation test kit market is projected to reach a value of approximately $2.5 billion in 2024. Anticipating robust growth, it is expected to expand significantly, reaching around $4.6 billion by 2034. This represents a Compound Annual Growth Rate (CAGR) of about 6.5% during the 2025-2034 forecast period.
Exactitude Consultancy., Ltd. released a research report offers a comprehensive examination of the various processes and materials used in the production of…
Global Inflammation Supplement Market - Natural Solutions for Chronic Inflammati …
The Global Inflammation Supplement Market reached at a CAGR during the forecast period 2024-2031.
Inflammation Supplement Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research methods, it offers comprehensive reports that help clients…
Shaping the Ocular Inflammation Treatment Market in 2025: Advancements In Ocular …
How Big Is the Ocular Inflammation Treatment Market Expected to Be, and What Will Its Growth Rate Be?
The market size for the treatment of ocular inflammation has significantly expanded in the past few years. The market will witness growth from $9.38 billion in 2024 to $9.97 billion in 2025, with a compound annual growth rate (CAGR) of 6.3%. The progressive growth within the historical timeframe can be credited to factors…
Green Coffee: Improved Brain Function and Reduced Inflammation
Green coffee is coffee that has not been roasted. The coffee beans are left in their natural state, which means they are not exposed to the high temperatures that occur during the roasting process. This results in a coffee that has a lower acidity level and a more subtle flavor. Many people believe that green coffee has a number of health benefits, including weight loss, improved brain function, and reduced…
Global Clinical Trials Cardiovascular Inflammation Review, H1, 2017
"The Report Cardiovascular Inflammation Global Clinical Trials Review, H1, 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
GlobalData's clinical trial report, Cardiovascular Inflammation Global Clinical Trials Review, H1, 2017" provides an overview of Cardiovascular Inflammation clinical trials scenario. This report provides top line data relating to the clinical trials on Cardiovascular Inflammation. Report includes an overview of trial numbers and…
